TrialArthritis & rheumatology (Hoboken, N.J.)2017

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.

Roy Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.